Skip Navigation


Carcinogenesis Advance Access originally published online on July 6, 2005
Carcinogenesis 2006 27(1):123-130; doi:10.1093/carcin/bgi176
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
27/1/123    most recent
bgi176v2
bgi176v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Herwaarden, A. E.v.
Right arrow Articles by Schinkel, A. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Herwaarden, A. E.v.
Right arrow Articles by Schinkel, A. H.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Carcinogenesis vol.27 no.1 © Oxford University Press 2005; all rights reserved.

Breast cancer resistance protein (Bcrp1/Abcg2) reduces systemic exposure of the dietary carcinogens aflatoxin B1, IQ and Trp-P-1 but also mediates their secretion into breast milk

Antonius E.van Herwaarden, Els Wagenaar, Barbara Karnekamp, Gracia Merino, Johan W. Jonker and Alfred H. Schinkel *

Division of Experimental Therapy, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands

* To whom correspondence should be addressed. Email: a.schinkel{at}nki.nl

The breast cancer resistance protein (BCRP/ABCG2) usually protects the body from a wide variety of environmental and dietary xenotoxins by reducing their net uptake from intestine and by increasing their hepatobiliary, intestinal and renal elimination. BCRP is also highly expressed in lactating mammary glands in mice, and this expression is conserved in cows and humans. As a result, BCRP substrates can be secreted into milk. We investigated whether different classes of dietary carcinogens are substrates of Bcrp1/BCRP and the implications for systemic exposure and breast milk contamination. Using polarized cell lines, we found that Bcrp1 transports the heterocyclic amines 2-amino-3-methylimidazo[4,5-f]quinoline (IQ) and 3-amino-1,4-dimethyl-5H-pyrido[4,3-b]indole (Trp-P-1) and the potent human hepatocarcinogen aflatoxin B1, and decreases their cellular accumulation up to 10-fold. In vivo pharmacokinetic studies showed that [14C]IQ, [14C]Trp-P-1 and [3H]aflatoxin B1 plasma levels were substantially lower in wild-type compared with Bcrp1–/– mice, after both oral and intravenous administration, demonstrating that Bcrp1 restricts systemic exposure to these carcinogens. Moreover, Bcrp1 mediates transfer of [14C]IQ, [14C]Trp-P-1 and [3H]aflatoxin into milk, with 3.4 ± 0.6, 2.6 ± 0.3 and 3.8 ± 0.5-fold higher milk to plasma ratios, respectively, in lactating wild-type versus Bcrp1–/– mice. We have thus identified Bcrp1/BCRP as one of the molecular mechanisms by which heterocyclic amines and aflatoxin are transferred into milk, thereby posing a health risk to breast-fed infants and dairy consumers. Paradoxically, Bcrp1/BCRP appears to have both protective and adverse roles with respect to exposure to dietary carcinogens.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
J. Enokizono, H. Kusuhara, A. Ose, A. H. Schinkel, and Y. Sugiyama
Quantitative Investigation of the Role of Breast Cancer Resistance Protein (Bcrp/Abcg2) in Limiting Brain and Testis Penetration of Xenobiotic Compounds
Drug Metab. Dispos., June 1, 2008; 36(6): 995 - 1002.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
X. Liu, C. Chen, and B. J. Smith
Progress in Brain Penetration Evaluation in Drug Discovery and Development
J. Pharmacol. Exp. Ther., May 1, 2008; 325(2): 349 - 356.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
L.-L. Hu, X.-X. Wang, X. Chen, J. Chang, C. Li, Y. Zhang, J. Yang, W. Jiang, and S.-M. Zhuang
BCRP gene polymorphisms are associated with susceptibility and survival of diffuse large B-cell lymphoma
Carcinogenesis, August 1, 2007; 28(8): 1740 - 1744.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
J. Enokizono, H. Kusuhara, and Y. Sugiyama
Regional Expression and Activity of Breast Cancer Resistance Protein (Bcrp/Abcg2) in Mouse Intestine: Overlapping Distribution with Sulfotransferases
Drug Metab. Dispos., June 1, 2007; 35(6): 922 - 928.
[Abstract] [Full Text] [PDF]


Home page
Toxicol SciHome page
B. Ebert, A. Seidel, and A. Lampen
Phytochemicals Induce Breast Cancer Resistance Protein in Caco-2 Cells and Enhance the Transport of Benzo[a]pyrene-3-sulfate
Toxicol. Sci., April 1, 2007; 96(2): 227 - 236.
[Abstract] [Full Text] [PDF]


Home page
J Antimicrob ChemotherHome page
J. Weiss, J. Rose, C. H. Storch, N. Ketabi-Kiyanvash, A. Sauer, W. E. Haefeli, and T. Efferth
Modulation of human BCRP (ABCG2) activity by anti-HIV drugs
J. Antimicrob. Chemother., February 1, 2007; 59(2): 238 - 245.
[Abstract] [Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.